Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at PLN 36.7B, ahead of BioNTech (PLN 34.2B) and Gilead Sciences (PLN 30.4B). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenPLN 36.7B
- Median
- PLN 1.7B
- Combined market value
- PLN 3.38T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | PLN 36.7B | PLN 970.5B | PLN 1,794.15 | 2.52% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | PLN 34.2B | PLN 83.6B | PLN 337.17 | 1.14% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | PLN 30.4B | PLN 842.6B | PLN 679.29 | 0.73% down | 33% up | ||
| 4 | argenxARGX · Health Care | PLN 14B | PLN 239.3B | PLN 3,805.97 | 0.06% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | PLN 12.1B | PLN 149.8B | PLN 1,013.29 | 0.53% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | PLN 10.4B | PLN 324.8B | PLN 802.78 | 3.42% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | PLN 3.6B | PLN 27.8B | PLN 134.52 | 0.78% up | 43% up | ||
| 8 | QiagenQGEN · Health Care | PLN 3.4B | PLN 41.2B | PLN 199.76 | 0.10% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | PLN 2.9B | PLN 66.7B | PLN 659.04 | 1.18% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | PLN 2.3B | PLN 44.6B | PLN 696.94 | 6.92% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | PLN 2B | PLN 37.6B | PLN 1,267.35 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | PLN 1.9B | PLN 67.7B | PLN 277.41 | 0.76% up | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | PLN 1.5B | PLN 139.6B | PLN 645.37 | 1.30% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | PLN 1.4B | PLN 41.9B | PLN 490.75 | 0.48% up | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | PLN 1.4B | PLN 16.2B | PLN 166.62 | 3.25% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | PLN 1.3B | PLN 23.3B | PLN 191.20 | 5.52% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | PLN 1.1B | PLN 46B | PLN 292.62 | 0.24% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | PLN 843.5M | PLN 25.4B | PLN 388.74 | 0.08% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | PLN 735.7M | PLN 32.4B | PLN 475.92 | 5.72% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | PLN 699.2M | PLN 37.4B | PLN 235.99 | 1.15% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | PLN 537.9M | PLN 44.2B | PLN 387.26 | 0.40% up | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | PLN 355M | PLN 28.7B | PLN 26.99 | 7.27% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | PLN 283.3M | PLN 18.7B | PLN 115.73 | 1.07% up | 88% up | ||
| 24 | CG OncologyCGON · Health Care | PLN 130.6M | PLN 28.8B | PLN 322.46 | 1.63% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0193 PLN).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (PLN 36.7B), BioNTech (PLN 34.2B) and Gilead Sciences (PLN 30.4B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 18:41 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of PLN 3.38T as of 18 Nov 2026, 18:41 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.